Back to Search Start Over

Detecting Crystallinity Using Terahertz Spectroscopy in 3D Printed Amorphous Solid Dispersions

Authors :
Supawan Santitewagun
Rishi Thakkar
J. Axel Zeitler
Mohammed Maniruzzaman
Source :
Molecular Pharmaceutics. 19:2380-2389
Publication Year :
2022
Publisher :
American Chemical Society (ACS), 2022.

Abstract

This study demonstrates the applicability of terahertz time-domain spectroscopy (THz-TDS) in evaluating the solid-state of the drug in selective laser sintering-based 3D printed dosage forms. Selective laser sintering is a powder bed-based 3D printing platform, which has recently demonstrated applicability in manufacturing amorphous solid dispersions (ASDs) through a layer-by-layer fusion process. When formulating ASDs, it is critical to confirm the final solid state of the drug as residual crystallinity can alter the performance of the formulation. Moreover, SLS 3D printing does not involve the mixing of the components during the process, which can lead to partially amorphous systems causing reproducibility and storage stability problems along with possibilities of unwanted polymorphism. In this study, a previously investigated SLS 3D printed ASD was characterized using THz-TDS and compared with traditionally used solid-state characterization techniques, including differential scanning calorimetry (DSC) and powder X-ray diffractometry (pXRD). THz-TDS provided deeper insights into the solid state of the dosage forms and their properties. Moreover, THz-TDS was able to detect residual crystallinity in granules prepared using twin-screw granulation for the 3D printing process, which was undetectable by the DSC and XRD. THz-TDS can prove to be a useful tool in gaining deeper insights into the solid-state properties and further aid in predicting the stability of amorphous solid dispersions.

Details

ISSN :
15438392 and 15438384
Volume :
19
Database :
OpenAIRE
Journal :
Molecular Pharmaceutics
Accession number :
edsair.doi.dedup.....77a6cffcf82be434e62adcca12ea0361
Full Text :
https://doi.org/10.1021/acs.molpharmaceut.2c00163